- Home
- GENK vs PMI Comparison
GENK vs PMI Comparison
Compare GENK & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GENK | PMI |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | 2700 | 75 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | PMI |
|---|---|---|
| Price | $1.96 | $0.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 36.3K | ★ 12.6M |
| Earning Date | 05-13-2026 | 06-18-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $0.11 |
| 52 Week High | $4.98 | $13.68 |
Technical Indicators
Market Signals| Indicator | GENK | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 46.58 | 23.95 |
| Support Level | $1.53 | N/A |
| Resistance Level | $2.30 | $0.27 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 1.15 | 33.18 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.